In line with this mechanism, two anti-angiogenic agents were approved by the FDA for the treatment of advanced NSCLC: bevacizumab [an anti-VEGF-A monoclonal antibody (mAb)] and ramucirumab (an anti-VEGFR-2 mAb) (22, 23). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.